Eli Lilly’s Mounjaro cuts risk of developing Type 2 diabetes, study finds

Eli Lilly’s stock gained more than 2% premarket on Tuesday after the drugmaker said that tirzepatide, marketed as the diabetes drug Mounjaro and weight-loss treatment Zepbound, sharply cut patients’ risk of developing Type 2 diabetes in a late-stage trial.

​MarketWatch.com – Top Stories

Read More